Dermtreat continues study of OLP treatment patch

Following successful results from the first phase of a clinical study of the clobetasol-loaded Rivelin® patch in patients suffering from Oral Lichen Planus, Danish-based Dermtreat has announced continuing the study for a second phase.

The Rivelin® patch is a breakthrough therapy for the treatment of mucosal diseases.

“Having a patch adhering for up to 2 hours directing delivery of clobetasol would be a huge advantage over current off-label treatment strategies; it would improve the efficacy of clobetasol significantly.” says US lead investigator and oral medicine specialist, professor Mike Brennan of Carolina Healthcare System, Charlotte.

Read the full press release of January, 2018, here.